Simulations Plus subsidiary DILIsym was awarded a Fast-Track SBIR grant to fund the development of software for predicting drug-induced kidney injury.
![Simulations Plus Enters Funded Research Collaboration with Large European Consortium](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Enters Funded Research Collaboration with Large European Consortium
Enhancements to mechanistic dermal absorption model in GastroPlus™ will target non-pharmaceutical markets
![Simulations Plus Reports Third Quarter FY2018 Financial Results](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Reports Third Quarter FY2018 Financial Results
Record quarter as revenues grow 26.7%, 9MoFY18 net income up 63.8%
Board of Directors Announces Quarterly Dividend of $0.06 Per Share
![Simulations Plus to Report Third Quarter 2018 Financial Results](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus to Report Third Quarter 2018 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its third quarter financial results for fiscal year 2018, the period ended May 31, 2018, after the close of the financial markets on Tuesday, July 10, 2018.
![Simulations Plus Releases ADMET Predictor™ Version 9](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Releases ADMET Predictor™ Version 9
Improvements to AI technology and extensions to HTPK Simulation Module further support discovery research efforts
![Simulations Plus Names Shawn O’Connor as CEO](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Names Shawn O’Connor as CEO
Executive with relevant expertise in multiple industries succeeds retiring CEO Walt Woltosz, who remains chairman of the board
![Simulations Plus Releases GastroPlus™ Version 9.6](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Releases GastroPlus™ Version 9.6
Significant improvements support internal research activities through regulatory interactions
![US FDA Procures DILIsym Software License Package](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
US FDA Procures DILIsym Software License Package
US FDA Continues Its Goal of Propelling Model-Based Drug Development Forward
![Simulations Plus Announces Employee Bonuses](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Announces Employee Bonuses
Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical discovery and development, today announced that it will be distributing a one-time $1,000 discretionary cash bonus to each of its employees.
![Simulations Plus, Inc. to Host Earnings Call](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus, Inc. to Host Earnings Call
Simulations Plus, Inc. (NASDAQ: SLP) will be discussing their earnings results in their Q2 Earnings Call to be held on April 9, 2018, at 4:15 PM Eastern Time.
![Simulations Plus Reports Record Second Quarter FY2018 Revenue](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Reports Record Second Quarter FY2018 Revenue
Board of Directors Announces Quarterly Dividend of $0.06 Per Share
![Data Projects Medical Technologies Market to Expand](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Data Projects Medical Technologies Market to Expand
FinancialBuzz.com News Commentary
![Simulations Plus Launches Version 2.0 of PKPlus™](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Launches Version 2.0 of PKPlus™
Major update to preclinical and clinical trial data analysis software addresses user requests
![DILIsym Services Inc., a Simulations Plus Company, Releases DILIsym® Version 7A](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
DILIsym Services Inc., a Simulations Plus Company, Releases DILIsym® Version 7A
Significant update of liver safety program includes performance and capability enhancements